Search

everythinglearnresearchcommunity

for

Search:↓

A postmenopausal woman's facial redness, acne, and excess hair were caused by too much hormone therapy for insomnia, but improved after stopping the treatment.

Amenorrhea is relatively rare and initial testing should check FSH, TSH, and prolactin levels.

Over-the-counter products can help with menopause symptoms, but be aware of their ingredients.

A postmenopausal woman's excessive hair growth and hair loss were due to a non-cancerous ovarian condition, treated successfully with surgery.

Testosterone therapy can improve sexual satisfaction and mood in surgically menopausal women when used with estrogen, but its long-term safety and effects on naturally menopausal and premenopausal women are unclear.

Agmatine may help reduce seizures linked to hormone changes in female rats.

Leydig cells can cause testosterone-secreting adrenal tumors in women.

Finasteride doesn't affect ovulation in normal women.

The document concludes that identifying the cause of amenorrhea is crucial for proper treatment.

Androgen therapy can help with symptoms like low libido in women, but more research is needed to understand its long-term safety and effects on health.

The main cause of excessive hair growth in Turkish women is Polycystic ovary syndrome, but in about one fifth of cases, the reason for high male hormone levels is unknown.

Amenorrhea, or the absence of periods, should be evaluated by age 15 or within five years of early breast development, and is most commonly caused by conditions like polycystic ovary syndrome and hypothalamic amenorrhea.

A woman had both Graham Little-Piccardi-Lassueur syndrome, causing hair loss, and complete androgen insensitivity syndrome, making her genetically male but physically female. This suggests androgens don't affect the hair loss condition.

Amenorrhea is when a woman doesn't have periods, with primary amenorrhea starting by age 15 or within five years of breast development, and secondary amenorrhea when periods stop for three months. It affects 3-4% of women not pregnant, breastfeeding, or in menopause, mainly due to polycystic ovary syndrome, hypothalamic amenorrhea, hyperprolactinemia, and ovarian failure.

Oral retinoic acid effectively treated collodion baby, with hair loss as the main side effect.

Metabolic syndrome and PCOS are related but separate conditions, with metabolic syndrome increasing the risk of heart disease and diabetes.

PRP therapy shows promise in healing and tissue repair across various medical fields but needs more research for standardization and optimization.

Any medication can cause skin reactions, some due to allergies and others due to dosage or genetic factors.

Higher doses of spironolactone may improve acne in PCOS patients, but side effects are a concern.

Women with nonclassic congenital adrenal hyperplasia experience more sexual dysfunction and distress.

GnRH analogues are effective for diagnosing and treating female androgen excess, offering a non-surgical option.

Lack or blocking of SRD5a, a key component in hormone creation, can lead to conditions like pseudohermaphrodism and affect hair growth, bone mass, muscle strength, and reproductive health. More research is needed on its regulation from fertilization to adulthood.

PRP is popular for hair restoration but needs better research methods to confirm its effectiveness and safety.

Premature ovarian insufficiency (POI) can harm women's sexual health, and they may benefit from hormone therapy and counseling.

Melatonin may help treat PCOS symptoms in rats.

Foxi3 expression in developing teeth and hair is controlled by the ectodysplasin pathway.

All women with Polycystic Ovary Syndrome (PCOS) in a study had at least one skin disorder, with the most common being excessive hair growth, acne, dark skin patches, hair loss, and oily skin.

The review highlights the need for more research on transgender dermatology, the role of dermatologists in gender affirmation, and the effects of hormone therapy on skin and hair.

The study concluded that both anti-Mullerian hormone and LH/FSH ratio are higher in women with PCOS and combining these markers with BMI could improve diagnosis accuracy.

The article concludes that global standardization in PCOS research is crucial for accurate diagnosis and understanding of the condition.